| Investigator, Principal |
NCT04910048: Impact of a POPOP on Preoperative Health, Eligibility, and Clinical & Patient-Reported Outcomes in TJA |
|
|
| Active, not recruiting | N/A | 46 | US | POPOP (preoperative patient optimization program), 20Lighter, SOC (standard of care) | University of Arkansas | Osteoarthritis, Knee, Osteoarthritis, Hip, Avascular Necrosis, Rheumatoid Arthritis | 04/23 | 12/24 | | |
NCT06204900: A Post-marketing Study to Evaluate a Novel Surgical Monitoring Technique Using the EARP Nerve Cuff in TLIF Surgery. |
|
|
| Not yet recruiting | N/A | 30 | US | Nerve Cuff and Retractor System | Retropsoas Technologies, LLC | Undergoing a Single-level or Two-level TLIF Surgery | 06/24 | 08/24 | | |
ACAB, NCT04292405: Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator |
|
|
| Recruiting | N/A | 60 | US | Wearable Cardioverter Defibrillator, AUDICOR AM | Zoll Medical Corporation | Heart Failure | 03/24 | 05/24 | | |
| Recruiting | N/A | 60 | US | BHmApp | William Beaumont Hospitals, University of Pennsylvania | Urinary Incontinence | 08/24 | 08/24 | | |
| Recruiting | N/A | 200 | Europe | | Chelsea and Westminster NHS Foundation Trust, ViiV Healthcare | HIV Infections, Gender Identity, Human Immunodeficiency Virus | 04/24 | 10/25 | | |
| Active, not recruiting | N/A | 70 | US | PQ Bypass System | Endologix | Peripheral Artery Diseases | 06/24 | 06/24 | | |
NCT03586414: MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women |
|
|
| Active, not recruiting | N/A | 31 | US | MITOQUINOL MESYLATE then placebo, MitoQ, Mitoquinol methanesulfonate, Placebo, then MITOQUINOL MESYLATE | University of Colorado, Denver, University of Colorado Nutrition Obesity Research Center (NORC) | Diastolic Dysfunction | 07/25 | 08/25 | | |
NCT06361797: Varying Bone Marrow-Derived Mesenchymal Stem Cells Concentrations' Impact on Rotator Cuff Repair Outcomes |
|
|
| Not yet recruiting | N/A | 150 | US | Rotator cuff repair augmented with whole bone marrow, Whole bone marrow, Bone marrow aspirate, Rotator cuff repair augmented with concentrated bone marrow, Bone marrow-derived mesenchymal stem cells, Bone marrow concentrate | Johns Hopkins University, ON Foundation | Rotator Cuff Tears | 07/26 | 12/27 | | |
NCT06340503: Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors |
|
|
| Recruiting | N/A | 20 | US | Research-grade accelerometer, National Comprehensive Cancer Network (NCCN) Education Materials, Garmin Vivofit activity tracker, Exercise Consultation Calls, Interview, Physical Activity Index Assessment (Intervention Arm), Physical Activity Index Assessment (Control Arm), Health Surveys | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Breast Cancer, Colon Cancer | 07/25 | 08/25 | | |
NCT02945085: 3D Team Care for Cognitively Vulnerable Older Adults |
|
|
| Recruiting | N/A | 576 | US | Home Based Care Team, Telephone Based Care Team | UConn Health, Patient-Centered Outcomes Research Institute, University of Connecticut | Dementia, Depression, Delirium | 07/24 | 07/24 | | |
NCT04931251: Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings |
|
|
| Recruiting | N/A | 780 | US | Financial Navigation | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Neoplasms, Carcinoma | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 80 | US | Gaming in a virtual environment | Yale University, National Heart, Lung, and Blood Institute (NHLBI) | Cardiovascular Diseases | 07/25 | 07/25 | | |
NCT04927052: A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment |
|
|
| Completed | N/A | 136 | Canada | Revanesse Shape + with Lidocaine, Juvederm Voluma with Lidocaine. | Prollenium Medical Technologies Inc. | Volume Deficit in the Mid-face | 08/23 | 08/23 | | |
| Not yet recruiting | N/A | 16 | US | KeraStat cream, M-PART Assessments via MyCap, Clinical Assessments, Feedback phone interview | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Radiation Dermatitis | 08/26 | 08/26 | | |
| Active, not recruiting | N/A | 5000 | RoW | Edoxaban | Daiichi Sankyo, Inc., Daiichi Sankyo (China) Holdings Co., Ltd. | Non-valvular Atrial Fibrillation | 10/24 | 10/24 | | |
ROCK-RT, NCT05169177: Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy |
|
|
| Recruiting | N/A | 50 | RoW | | University of Sydney, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia, Princess Alexandra Hospital, Brisbane, Australia | Liver Neoplasm | 10/24 | 10/26 | | |
NCT01336790: International Lymphatic Disease and Lymphedema Registry |
|
|
| Recruiting | N/A | 5000 | US | | Stanford University, Lymphatic Education & Research Network | Lymphedema | 12/24 | 12/25 | | |
NCT05531357: Physiologic Mechanisms Underlying Ovarian Follicular Waves During the Menstrual Cycle |
|
|
| Completed | N/A | 50 | Canada | Transvaginal ultrasound scans, Finger-prick blood sampling for dried blood spots, Urine sampling, Venipunctures | University of Saskatchewan, Ansh Labs | Reproductive Issues | 03/24 | 03/24 | | |
| Recruiting | N/A | 200 | US | Education and counseling, Education | Georgetown University | Breast Cancer | 12/24 | 12/25 | | |
NCT05689190: Non-invasive Flow Measurements in Patients With Lower Extremity Arterial Disease (LEAD) |
|
|
| Recruiting | N/A | 30 | Europe | | Philips Clinical & Medical Affairs Global, Leiden University Medical Center | Lower Extremity Arterial Disease | 12/24 | 12/24 | | |
NCT05862467: A Pilot Participatory Program Evaluation of a Virtual Trauma Support Program for Autistic Adults |
|
|
| Recruiting | N/A | 30 | US | Written Exposure Therapy (WET) via telehealth | University of Wyoming | Autism, Trauma, Posttraumatic Stress Disorder, Posttraumatic Stress Symptom | 05/25 | 05/25 | | |
NCT04635111: A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment |
|
|
| Recruiting | N/A | 30 | US | TURALIO™ | Daiichi Sankyo, Inc. | Hepatotoxicity, Tenosynovial Giant Cell Tumor | 06/25 | 03/36 | | |
| Recruiting | N/A | 198 | US | Dietary Intervention Classes | University of South Carolina | Diabetes Mellitus, Type 2, Obesity | 12/25 | 03/26 | | |
MILOS, NCT04579367: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia |
|
|
| Recruiting | N/A | 5000 | Europe | Bempedoic acid and/or its fixed-dose combination with ezetimibe | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Hypercholesterolemia, Mixed Dyslipidemia | 09/25 | 09/25 | | |
NCT06054412: An Adjunctive Neurofeedback Training Program to Enhance Wellness Among Trauma-Exposed Postpartum Mothers |
|
|
| Recruiting | N/A | 20 | US | Neuroptimal (Zengar, Inc.) Neurofeedback | Wayne State University | Well-Being, Psychological, Dissociation, Maternal Care Patterns, Maternal Behavior, Maternal Distress, Mood Disturbance, Emotional Regulation, Post Traumatic Stress Disorder | 09/25 | 03/26 | | |
| Active, not recruiting | N/A | 7 | US | Actual device PFO closure, GORE® CARDIOFORM Septal Occluder, Thienopyridine (clopidogrel or prasugrel), Plavix, Effient, Sham device PFO closure | W.L.Gore & Associates | Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale | 12/25 | 08/26 | | |
SILVERCARE_AF, NCT05804747: A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation |
|
|
| Recruiting | N/A | 1100 | RoW | Edoxaban | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Atrial Fibrillation | 12/25 | 12/25 | | |
LEARN, NCT05184790: Learning Environment for Artificial Intelligence in Radiotherapy New Technology |
|
|
| Not yet recruiting | N/A | 300 | RoW | | University of Sydney, Princess Alexandra Hospital, Brisbane, Australia, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia | Arrhythmias, Cardiac, Breast Cancer, Prostatic Cancer, Brain Cancer, Kidney Cancer, Head and Neck Cancer, Liver Cancer, Pancreatic Cancer, Spinal Neoplasm | 01/26 | 01/26 | | |
NCT05022862: Economic Incentives and vDOT for Latent Tuberculosis Infection |
|
|
| Recruiting | N/A | 399 | US | Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Latent Tuberculosis | 04/26 | 10/26 | | |
NCT05993234: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) |
|
|
| Recruiting | N/A | 257 | Europe | Trastuzumab deruxtecan, T-DXd, ENHERTU® | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | 12/26 | 09/27 | | |
| Recruiting | N/A | 1350 | Europe | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer | 06/27 | 09/28 | | |
NCT05636397: Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC |
|
|
| Recruiting | N/A | 60 | Canada | L-Citrulline | The Hospital for Sick Children | BPD - Bronchopulmonary Dysplasia, Pulmonary Hypertension, NEC | 12/27 | 03/28 | | |
NCT05181163: Biofilm Formation and Antibiotic Sensitivity Patterns |
|
|
| Not yet recruiting | N/A | 100 | NA | swab | Sohag University | Orthopedic Surgery | 07/22 | 01/23 | | |
| Schaefer, Axel |
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin |
|
|
| Recruiting | 3 | 888 | Europe, US, RoW | Orforglipron, LY3502970, Dapagliflozin | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 10/25 | | |
NCT05371080 / 2021-005319-30: A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults |
|
|
| Active, not recruiting | 3 | 3038 | Europe, Canada, Japan, US, RoW | HZ/su vaccine | GlaxoSmithKline | Herpes Zoster | 08/27 | 08/27 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
NCT06389487: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above |
|
|
| Recruiting | 3 | 850 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA investigational vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 08/24 | 04/25 | | |
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities |
|
|
| Active, not recruiting | 3 | 700 | US | Tirzepatide, LY3298176, Semaglutide | Eli Lilly and Company | Obesity, Overweight | 11/24 | 11/24 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 06/25 | 06/25 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
| Grode, Leander |
| Active, not recruiting | 3 | 59 | Europe | VPM1002, Placebo | Vakzine Projekt Management GmbH, FGK Clinical Research GmbH | Infection, Respiratory Tract | 05/21 | 05/21 | | |
